secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRISTOL MYERS SQUIBB CO (BMY)
CIK:        0000014272
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0000014272-26-000008
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bristol Myers Q1 revenue $11.5B (+3%); reaffirms 2026 guidance trending upper end
--------------------------------------------------------------------------------

- Q1 revenue $11.5B, up 3% YoY (1% ex-FX); Growth Portfolio revenue $6.2B (+12% / +9% ex-FX).
- GAAP EPS $1.31; non-GAAP EPS $1.58; both include $(0.03) net impact from Acquired IPRD and licensing.
- FY 2026 guidance reaffirmed: revenue ~$46.0-47.5B, non-GAAP EPS $6.05-6.35, trending toward upper end.
- CEO highlights strong execution and pipeline milestones ahead for patients and shareholders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/14272/000001427226000008/0000014272-26-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/14272/000001427226000008/bmy-20260430.htm
  HTML page:      https://secwatch.observer/filing/0000014272-26-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer